Pangenomic Health Inc. NARA
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -69.48% | -68.06% | -88.86% | -24.48% | 134.07% |
| Gross Profit | 69.48% | 68.06% | 88.86% | 24.48% | -134.07% |
| SG&A Expenses | 92.84% | 261.78% | 532.04% | 1,245.75% | 70.86% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | -93.33% | -95.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.56% | 138.01% | 49.19% | 803.52% | 78.78% |
| Operating Income | -34.56% | -138.01% | -49.19% | -803.52% | -78.78% |
| Income Before Tax | -72.57% | -141.81% | -3.48% | -783.23% | 84.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.57% | -141.81% | -3.48% | -783.23% | 84.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.57% | -141.81% | -3.48% | -783.23% | 84.56% |
| EBIT | -34.56% | -138.01% | -49.19% | -803.52% | -78.78% |
| EBITDA | -34.57% | -138.06% | -49.20% | -814.87% | -81.23% |
| EPS Basic | 6.31% | 31.61% | 78.45% | -263.72% | 93.80% |
| Normalized Basic EPS | 6.20% | 31.54% | 68.28% | -261.27% | 39.72% |
| EPS Diluted | 6.31% | 31.61% | 78.45% | -263.72% | 93.80% |
| Normalized Diluted EPS | 6.20% | 31.54% | 68.28% | -261.27% | 39.72% |
| Average Basic Shares Outstanding | 83.71% | 253.93% | 380.22% | 143.42% | 149.00% |
| Average Diluted Shares Outstanding | 83.71% | 253.93% | 380.22% | 143.42% | 149.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |